← ANALYST RATINGS · TIPRANKS
Kura Oncology (KURA): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy0 Hold0 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $26.82, the highest $40.00, the lowest $12.15. The average is +195.3% from the last price of $9.08.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $10.00 → $9.50−5.0% | Hold | +4.6% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $10.00 → $9.50−5.0% | Hold | +4.6% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $10.00 → $9.50−5.0% | Hold | +4.6% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.00 → $9.00−10.0% | Hold | −0.9% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $10.50 → $9.50−9.5% | Hold | +4.6% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $10.00 → $9.50−5.0% | Hold | +4.6% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $31.00 | Buy | +241.4% | Reiterated | 14.10.26on TipRanks 06:45 | −1.2%next day +0.7% | ↗ |
| Priyanka Grover★★★★★★★★★★#12059 · hits 12% · avg −46.0% | J.P. Morgan | $30.00 | Buy | +230.4% | Reiterated | 13.10.26on TipRanks Oct 14 08:25 | −5.4%next day −1.2% | ↗ |
| Daniel Brims★★★★★★★★★★#12312 · hits 19% · avg −36.9% | Lake Street | $23.00 | Buy | +153.3% | Reiterated | 10.09.26on TipRanks 09:11 | −3.7%next day −2.4% · 5 days +0.7% | ↗ |
| Unknown Analyst | Leerink Partners | $12.15 | Buy | +33.8% | Reiterated | 10.09.26on TipRanks 09:11 | −3.7%next day −2.4% · 5 days +0.7% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $28.00 | Buy | +208.4% | Reiterated | 10.09.26on TipRanks 05:37 | −3.7%next day −2.4% · 5 days +0.7% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $40.00 | Buy | +340.5% | Reiterated | 09.09.26on TipRanks 10:35 | −3.0%next day −3.7% · 5 days −6.3% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $25.00 | Buy | +175.3% | Reiterated | 31.08.26on TipRanks 10:30 | +0.2%next day +2.6% · 5 days −0.9% | ↗ |
| David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% | UBS | $15.00 | Buy | +65.2% | Assigned | 21.08.26on TipRanks 07:55 | +1.1%next day +4.6% · 5 days +6.0% | ↗ |
| Charles Zhu★★★★★★★★★★#351 · hits 64% · avg +25.8% | LifeSci Capital | $28.00 | Buy | +208.4% | Reiterated | 13.08.26on TipRanks 06:35 | +0.8%next day +7.8% · 5 days +18.0% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 12.08.26on TipRanks Aug 13 10:35 | −0.2%next day +0.8% · 5 days +26.5% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $36.00 | Buy | +296.5% | Reiterated | 28.07.26on TipRanks 09:55 | −8.5%next day −2.5% · 5 days −2.4% | ↗ |
| Unknown Analyst | Jefferies | $28.00 | Buy | +208.4% | Reiterated | 15.06.26on TipRanks Jun 17 09:30 | +3.7%next day −0.9% · 5 days +11.4% | ↗ |
| Unknown Analyst | Guggenheim | — | Hold | — | Reiterated | 06.03.26on TipRanks 07:45 | +6.6%next day +3.9% · 5 days −2.0% | ↗ |
| Justin Zelin★★★★★★★★★★#4442 · hits 36% · avg +3.1% | BTIG | — | Hold | — | Reiterated | 09.12.25on TipRanks Dec 10 06:05 | −8.2%next day 0.0% · 5 days +0.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Kura Oncology
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $26.81 at a price of $10.71 (+150.4%); now: $26.82 at $9.08 (+195.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 25 | 32 | 34 | 28 | 17 | 13 |
| Buy | 2 | 1 | 1 | 2 | 3 | 3 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.82 (from $-0.99 to $-0.70). Last quarter: $-0.77.
Sales
Next quarter’s sales estimate — $25M (from $18M to $29M). Last quarter: $21M.
Best top-analyst consensus in the sector · Healthcare
About Kura Oncology
- CEO: Troy Wilson
- Employees: 260
- 4930 Directors Place, San Diego, CA, 92121, US
- kuraoncology.com
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Data from the stock’s TipRanks forecast page, read 62 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗